此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

High-Intensity Peripheral Magnetic Stimulation in Traumatic Peripheral Nerve Injury

Clinical and Electrophysiological Evaluation of the Effect of High-Intensity Peripheral Magnetic Stimulation in Traumatic Peripheral Nerve Injury: A Randomized, Double-Blind, Sham-Controlled Trial

Traumatic peripheral nerve injury is a common cause of chronic neuropathic pain, muscle weakness, and functional limitation, particularly in young and active individuals. Current conservative and pharmacological treatments often provide incomplete relief or carry side effects. High-intensity peripheral magnetic stimulation (PMS) is a non-invasive method that may help reduce neuropathic pain and support motor recovery, but evidence in traumatic nerve injury is limited.

This randomized, double-blind, sham-controlled trial aims to evaluate whether high-intensity PMS, added to a standardized therapeutic exercise program, improves pain, function, quality of life, and electrophysiological measures in adults with traumatic peripheral nerve injury. Participants will be randomly assigned to receive either active PMS or sham PMS, in addition to the same exercise program. Outcomes will be assessed at baseline, 4 weeks, and 8 weeks.

研究概览

详细说明

This is a prospective, randomized, double-blind, sham-controlled clinical trial conducted at a single center. Adults aged 18-65 years with unilateral traumatic peripheral nerve injury confirmed by electromyography, with symptom onset at least 3 months prior, neuropathic pain (DN4 ≥ 4), pain severity (VAS ≥ 4), and reduced muscle strength (MRC < 5) will be enrolled.

Participants will be randomly allocated using computer-generated randomization to one of two groups: (1) active high-intensity PMS plus a standardized therapeutic exercise program, or (2) sham PMS plus the same exercise program. Active stimulation will be delivered using a high-intensity magnetic stimulation system with a predefined neuropathy protocol (approximately 10 minutes per session, variable frequencies 1-60 Hz) applied over the injured peripheral nerve, for a total of 9 sessions over 3 weeks (3 sessions per week). In the sham group, the applicator coil will be reversed to prevent effective delivery of the magnetic field, while device screen and audible feedback are maintained. Both groups will receive an individualized exercise program (active range of motion, strengthening, stretching, proprioception and balance exercises, and occupational therapy) for 20 minutes per day, 5 days per week, over 3 weeks.

Participants and outcome assessors will be blinded to group allocation. The physiotherapist delivering the intervention will be aware of allocation but will not participate in assessments. Electrophysiological evaluations will be performed by a blinded electroneurophysiologist.

The primary outcome is pain severity measured by the Visual Analog Scale (VAS). Secondary outcomes include the Douleur Neuropathique 4 (DN4) questionnaire, the Brief Pain Inventory (BPI), the Nottingham Health Profile (NHP), Manual Muscle Testing (MRC scale), and electrophysiological parameters including compound muscle action potential (CMAP) amplitude, distal latency, nerve conduction velocity (NCV), and quantitative motor unit potential (MUP) analysis. Assessments will be performed at baseline (week 0), week 4, and week 8. A total of 40 participants (20 per group) is planned based on an a priori sample size calculation.

研究类型

介入性

注册 (估计的)

40

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Ankara、土耳其(türkiye)、06800
        • Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age between 18 and 65 years
  • Traumatic peripheral nerve injury
  • Unilateral traumatic peripheral neuropathy confirmed by electromyography (EMG)
  • Nerve injury occurring at least 3 months prior
  • Douleur Neuropathique 4 (DN4) score ≥ 4
  • Visual Analog Scale (VAS) score ≥ 4
  • Manual Muscle Testing score < 5
  • No analgesic use, or stable analgesic therapy for the past month (no dose changes)

Exclusion Criteria:

  • Active infection or malignancy
  • Metal implant or shrapnel in the application area
  • Electronic implants (e.g., cardiac pacemaker, spinal cord stimulator, deep brain stimulator)
  • Central nervous system diseases
  • Non-traumatic causes of neuropathy (e.g., radiculopathy, diabetic neuropathy, entrapment neuropathies, HIV-related neuropathy, trigeminal neuralgia)
  • Complete nerve injury
  • Injury involving three or more peripheral nerves or plexus injury
  • History of peripheral nerve surgery or injection within the past 3 months
  • Active psychiatric illness
  • Coagulopathy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Active PMS plus Therapeutic Exercise
Participants receive high-intensity peripheral magnetic stimulation (PMS) applied over the injured peripheral nerve using a predefined neuropathy protocol (approximately 10 minutes per session, variable frequencies 1-60 Hz), for a total of 9 sessions over 3 weeks (3 sessions per week). Stimulation intensity is increased until motor activity is elicited and kept constant during the session. In addition, participants receive a standardized therapeutic exercise program (active range of motion, strengthening, stretching, proprioception and balance exercises, and occupational therapy) for 20 minutes per day, 5 days per week, over 3 weeks.
High-intensity peripheral magnetic stimulation delivered via an inductive coil placed over the injured peripheral nerve, using a predefined neuropathy protocol (approximately 10 minutes per session, variable frequencies 1-60 Hz). Stimulation intensity is increased until motor activity is elicited and kept constant during the session. Applied 3 times per week for 3 weeks (9 sessions total).
Standardized individualized therapeutic exercise program including active range of motion exercises, strengthening exercises, stretching exercises, proprioception and balance exercises, and occupational therapy for activities of daily living. Delivered for 20 minutes per day, 5 days per week, over 3 weeks.
假比较器:Sham PMS plus Therapeutic Exercise
Participants receive sham peripheral magnetic stimulation using the same device, session duration, and application site, but with the applicator coil reversed to prevent effective delivery of the magnetic field to the target tissue. Device screen and audible feedback are maintained to preserve blinding. In addition, participants receive the same standardized therapeutic exercise program (active range of motion, strengthening, stretching, proprioception and balance exercises, and occupational therapy) for 20 minutes per day, 5 days per week, over 3 weeks.
Standardized individualized therapeutic exercise program including active range of motion exercises, strengthening exercises, stretching exercises, proprioception and balance exercises, and occupational therapy for activities of daily living. Delivered for 20 minutes per day, 5 days per week, over 3 weeks.
Sham peripheral magnetic stimulation using the same device, session duration, and application site, with the applicator coil reversed to prevent effective delivery of the magnetic field to the target tissue. Device screen and audible feedback are maintained to preserve blinding. Applied 3 times per week for 3 weeks (9 sessions total).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Pain Severity Measured by Visual Analog Scale (VAS)
大体时间:Baseline, week 4, and week 8
Pain severity assessed using the Visual Analog Scale (VAS), a 0-10 cm scale where 0 indicates "no pain" and 10 indicates "unbearable pain." Higher scores indicate greater pain severity.
Baseline, week 4, and week 8

次要结果测量

结果测量
措施说明
大体时间
Change in Neuropathic Pain Assessed by Douleur Neuropathique 4 (DN4)
大体时间:Baseline, week 4, and week 8
Neuropathic pain assessed using the Douleur Neuropathique 4 questionnaire, a 10-item instrument based on patient-reported symptoms and clinical examination findings. Scores range from 0 to 10, with a total score of 4 or higher indicating neuropathic pain. Higher scores indicate a worse outcome.
Baseline, week 4, and week 8
Change in Pain Severity and Interference Assessed by Brief Pain Inventory (BPI)
大体时间:Baseline, week 4, and week 8
Pain severity and pain interference assessed using the Brief Pain Inventory Short Form. Pain severity is scored from 0 to 10 (0 = no pain, 10 = pain as bad as you can imagine) and pain interference is scored from 0 to 10 (0 = does not interfere, 10 = completely interferes) across general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher scores indicate a worse outcome.
Baseline, week 4, and week 8
Change in Health-Related Quality of Life Assessed by Nottingham Health Profile (NHP)
大体时间:Baseline, week 4, and week 8
Health-related quality of life assessed using the Nottingham Health Profile. Each of the six sections (pain, physical mobility, energy level, sleep, social isolation, and emotional reactions) is scored from 0 to 100. Higher scores indicate a worse outcome (greater impairment in quality of life).
Baseline, week 4, and week 8
Change in Muscle Strength Assessed by Manual Muscle Testing (MRC Scale)
大体时间:Baseline, week 4, and week 8
Muscle strength assessed by manual muscle testing using the Medical Research Council scale in muscle groups innervated by the affected peripheral nerve. Scores range from 0 (no visible contraction) to 5 (full strength against resistance). Higher scores indicate a better outcome.
Baseline, week 4, and week 8
Change in Compound Muscle Action Potential (CMAP) Amplitude
大体时间:Baseline, week 4, and week 8
CMAP amplitude of the affected nerve measured by nerve conduction studies, reported in millivolts (mV). Higher values indicate better motor nerve function.
Baseline, week 4, and week 8
Change in Distal Motor Latency
大体时间:Baseline, week 4, and week 8
Distal motor latency of the affected nerve measured by nerve conduction studies, reported in milliseconds (ms). Higher values indicate worse nerve conduction.
Baseline, week 4, and week 8
Change in Nerve Conduction Velocity (NCV)
大体时间:Baseline, week 4, and week 8
Motor nerve conduction velocity of the affected nerve measured by nerve conduction studies, reported in meters per second (m/s). Higher values indicate better nerve conduction.
Baseline, week 4, and week 8
Change in Mean Motor Unit Potential (MUP) Duration
大体时间:Baseline, week 4, and week 8
Mean duration of motor unit potentials in the affected muscle, assessed by quantitative needle electromyography and reported in milliseconds (ms). Increased duration indicates chronic reinnervation.
Baseline, week 4, and week 8
Change in Mean Motor Unit Potential (MUP) Amplitude
大体时间:Baseline, week 4, and week 8
Mean amplitude of motor unit potentials in the affected muscle, assessed by quantitative needle electromyography and reported in microvolts (µV). Increased amplitude indicates chronic reinnervation.
Baseline, week 4, and week 8

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nurdan Korkmaz、Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2026年7月7日

首先提交符合 QC 标准的

2026年7月13日

首次发布 (实际的)

2026年7月15日

研究记录更新

最后更新发布 (实际的)

2026年7月15日

上次提交的符合 QC 标准的更新

2026年7月13日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅